Collectively, these data indicated that the targeted degradation of IGF-1R/IR by Ad-PTB-U-box significantly inhibit the in vivo tumor growth of IGF-1R/IR-overexpressing cancer cells, implying its potential as a therapeutic agent. This evidence concerns the gene IGF1R and cancer.